These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35435272)

  • 41. The Prospective Effect of Allopurinol on the Oxidative Stress Index and Endothelial Dysfunction in Covid-19.
    Al-Kuraishy HM; Al-Gareeb AI; Al-Niemi MS; Aljowaie RM; Almutairi SM; Alexiou A; Batiha GE
    Inflammation; 2022 Aug; 45(4):1651-1667. PubMed ID: 35199285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of Predictive Markers of Response to Immunomodulators in the Treatment of COVID-19 Patients.
    Caballero-Bermejo AF; Sancho-Lopez A; Ferrer-Armengou L; Jimenez-Martin ML; Fernandez-Cruz A; Ruiz-Antoran B
    Clin Lab; 2022 Sep; 68(9):. PubMed ID: 36125152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inflammatory and vascular biomarkers in post-COVID-19 syndrome: A systematic review and meta-analysis of over 20 biomarkers.
    Yong SJ; Halim A; Halim M; Liu S; Aljeldah M; Al Shammari BR; Alwarthan S; Alhajri M; Alawfi A; Alshengeti A; Khamis F; Alsalman J; Alshukairi AN; Abukhamis NA; Almaghrabi FS; Almuthree SA; Alsulaiman AM; Alshehail BM; Alfaraj AH; Alhawaj SA; Mohapatra RK; Rabaan AA
    Rev Med Virol; 2023 Mar; 33(2):e2424. PubMed ID: 36708022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
    Khan FA; Stewart I; Fabbri L; Moss S; Robinson K; Smyth AR; Jenkins G
    Thorax; 2021 Sep; 76(9):907-919. PubMed ID: 33579777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Longitudinal monitoring of laboratory markers characterizes hospitalized and ambulatory COVID-19 patients.
    Velavan TP; Kuk S; Linh LTK; Lamsfus Calle C; Lalremruata A; Pallerla SR; Kreidenweiss A; Held J; Esen M; Gabor J; Neurohr EM; Shamsrizi P; Fathi A; Biecker E; Berg CP; Ramharter M; Addo MM; Kreuels B; Kremsner PG
    Sci Rep; 2021 Jul; 11(1):14471. PubMed ID: 34262116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Associations of Iron Related Biomarkers with Risk, Clinical Severity and Mortality in SARS-CoV-2 Patients: A Meta-Analysis.
    Zhou S; Li H; Li S
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience.
    Farid E; Sridharan K; Alsegai OA; Khawaja SA; Mansoor EJ; Teraifi NA; Qahtani MA; Salman JA
    Biomark Med; 2021 Jun; 15(8):541-549. PubMed ID: 33988463
    [No Abstract]   [Full Text] [Related]  

  • 49. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.
    Kharazmi AB; Moradi O; Haghighi M; Kouchek M; Manafi-Rasi A; Raoufi M; Shoaei SD; Hadavand F; Nabavi M; Miri MM; Salarian S; Shojaei S; Khalili S; Sistanizad M; Sadeghi S; Karagah A; Asgari S; Jaffaraghaei M; Araghi S
    Immun Inflamm Dis; 2022 Feb; 10(2):201-208. PubMed ID: 34762351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
    Borie R; Savale L; Dossier A; Ghosn J; Taillé C; Visseaux B; Jebreen K; Diallo A; Tesmoingt C; Morer L; Goletto T; Faucher N; Hajouji L; Neukirch C; Phillips M; Stelianides S; Bouadma L; Brosseau S; Ottaviani S; Pluvy J; Le Pluart D; Debray MP; Raynaud-Simon A; Descamps D; Khalil A; Timsit JF; Lescure FX; Descamps V; Papo T; Humbert M; Crestani B; Dieude P; Vicaut E; Zalcman G;
    PLoS One; 2020; 15(12):e0243961. PubMed ID: 33326457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19.
    Qeadan F; Tingey B; Gu LY; Packard AH; Erdei E; Saeed AI
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials.
    Yasmin F; Najeeb H; Moeed A; Hassan W; Khatri M; Asghar MS; Naveed AK; Ullah W; Surani S
    PLoS One; 2022; 17(4):e0266245. PubMed ID: 35381033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
    Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
    Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients : A meta-analysis.
    Nugroho J; Wardhana A; Maghfirah I; Mulia EPB; Rachmi DA; A'yun MQ; Septianda I
    Int J Lab Hematol; 2021 Feb; 43(1):110-115. PubMed ID: 32931146
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA.
    Rich C; Eriksson D; Dolfi F; Jablonska K; Dabbous F; Nazir J
    Clin Exp Immunol; 2022 Apr; 207(2):218-226. PubMed ID: 35020840
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis.
    Zhao Y; Yin L; Patel J; Tang L; Huang Y
    J Med Virol; 2021 Jul; 93(7):4358-4369. PubMed ID: 33739452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report.
    Franzetti M; Pozzetti U; Carugati M; Pandolfo A; Molteni C; Faccioli P; Castaldo G; Longoni E; Ormas V; Iemoli E; Piconi S
    Int J Infect Dis; 2020 Aug; 97():215-218. PubMed ID: 32422376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.